Showing results (151-160 of 164) with videos related to
Sort By:
Pageof 17
ESMO Open|March 4, 2017
Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO)Gilberto Morgan, Matteo Lambertini, Hampig Raphael Kourie, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2021
Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I StudyKeunchil Park, Eric B Haura, Natasha B Leighl, et al.Journal for Immunotherapy of Cancer|June 19, 2026
First-in-human study of lomvastomig, a PD-1-TIM-3 bispecific antibody, in patients with advanced and/or metastatic solid tumorsKristoffer Staal Rohrberg, Ignacio Melero, Miguel F Sanmamed, et al.The Lancet. Oncology|December 16, 2019
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trialsRobert C Doebele, Alexander Drilon, Luis Paz-Ares, et al.Journal of Fungi (Basel, Switzerland)|December 30, 2020
Polymorphisms within the TNFSF4 and MAPKAPK2 Loci Influence the Risk of Developing Invasive Aspergillosis: A Two-Stage Case Control Study in the Context of the aspBIOmics ConsortiumJose Manuel Sánchez-Maldonado, Ana Moñiz-Díez, Rob Ter Horst, et al.The Lancet. Oncology|June 17, 2020
COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort studyMarina Chiara Garassino, Jennifer G Whisenant, Li-Ching Huang, et al.Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|March 21, 2024
The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapyAna Gómez Rueda, Álvaro Taus, Rosa Álvarez Álvarez, et al.The Lancet. Respiratory Medicine|August 14, 2018
Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysisMichäel Duruisseaux, Anna Martínez-Cardús, Maria E Calleja-Cervantes, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 27, 2019
Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non-Small Cell Lung Carcinoma: the ROSING StudyEsther Conde, Susana Hernandez, Rebeca Martinez, et al.The Lancet. Oncology|January 31, 2012
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialRafael Rosell, Enric Carcereny, Radj Gervais, et al.Pageof 17